Revenue
$166.13K
Fiscal year ended 2026-06-30Operating income
-$6.20M
Fiscal year ended 2026-06-30Free cash flow
-$7.17M
Fiscal year ended 2026-06-30Valuation, from the filing
| Public float | $10.00M | Market value of stock held by non-affiliates, as stated on the cover page for 2025-06-30 |
|---|---|---|
| Float per share | $2.78 | Float divided by shares outstanding in the same filing. A floor under the share price on that date, not the price itself. |
| Float / revenue | 16.1× | A lower bound on the multiple, because affiliate holdings are excluded. |
| Float / equity | 0.5× | A lower bound on the multiple, because affiliate holdings are excluded. |
Every figure here is drawn from the 10-K cover page and the statements behind it, so each one traces to a filing. Public float counts only stock held by non-affiliates, which makes these floors rather than estimates: a high multiple is conclusive, a low one may mean cheap or may mean closely held. The float was measured on 2025-06-30, not today, and each multiple below it uses the figures for the fiscal year ending 2025-12-31 — the year that filing covered.
How this compares in its industry
Percentile among the Surgical & Medical Instruments & Apparatus filers on this site, highest value first. A high percentile means a large figure, which is good for a margin and not for leverage — the ranking says where the company sits, not whether that is where it should be.
| Measure | Reported | Percentile | |
|---|---|---|---|
| Operating margin | -8058.8% | 3th | |
| Net margin | -7533.6% | 3th | |
| R&D / revenue | 3074.3% | 97th | |
| FCF margin | -4793.2% | 3th | |
| Revenue YoY growth | -84.1% | 4th | |
| SBC / revenue | 361.1% | 96th | |
| CapEx / revenue | 112.5% | 96th | |
| Current ratio | 3.87x | 59th | |
| Gross margin | 64.3% | 59th |
Co-Diagnostics, Inc. (CODX) reported revenue of $166.13K and net income of -$6.28M for the fiscal year ended 2026-06-30. This page shows 10 annual periods of income statement, balance sheet and cash flow figures normalized from Co-Diagnostics, Inc.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Surgical & Medical Instruments & Apparatus.
Income
| Metric | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $166.13K | $145.95K | $263.92K | $145.38K | $162.91K | $50.28K | $149.32K | $641.14K | $2.66M | $467.85K |
| Cost of revenue | $45.30K | $193.77K | $142.40K | $26.28K | $32.11K | $21.59K | $255.07K | $297.40K | $212.15K | $234.50K |
| Gross profit | $120.83K | -$47.81K | $121.53K | $119.10K | $130.80K | $28.69K | -$105.74K | $343.74K | $2.44M | $233.35K |
| Operating income | -$6.20M | -$9.21M | -$26.54M | -$7.01M | -$8.06M | -$8.55M | -$11.91M | -$10.23M | -$7.68M | -$10.26M |
| Net income | -$6.28M | -$9.14M | -$25.75M | -$5.89M | -$7.73M | -$7.53M | -$11.03M | -$9.70M | -$7.60M | -$9.31M |
| Research & development | $4.15M | $5.93M | $5.10M | $4.48M | $4.69M | $4.87M | $4.81M | $4.88M | $5.61M | $5.68M |
| Weighted-average diluted shares | shares 4.31M | shares 2.25M | Unavailable | shares 37.89M | shares 1.10M | shares 1.07M | Unavailable | shares 30.49M | shares 30.12M | shares 29.84M |
| Pretax income | -$6.26M | -$9.14M | -$26.22M | -$7.05M | -$7.72M | -$7.52M | -$11.04M | -$9.67M | -$7.58M | -$9.29M |
| Income tax expense | $19.17K | $520 | -$473.72K | -$1.17M | $12.33K | $12.00K | -$8.18K | $22.19K | $20.59K | $22.76K |
| Diluted EPS | $-1.46 | $-4.06 | Unavailable | $-0.16 | $-7.00 | $-7.05 | Unavailable | $-0.32 | $-0.25 | $-0.31 |
| Selling, general & administrative | $1.97M | $2.97M | $2.41M | $2.38M | $3.21M | $3.43M | $6.64M | $5.35M | $4.17M | $4.48M |
| General & administrative | $1.50M | $2.50M | $1.87M | $1.82M | $2.60M | $2.77M | $5.82M | $4.29M | $3.13M | $2.92M |
| Selling & marketing | $466.68K | $467.96K | $545.45K | $568.94K | $609.71K | $657.03K | $818.67K | $1.06M | $1.04M | $1.56M |
Balance
| Metric | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $3.65M | $8.23M | $11.88M | $11.44M | $11.12M | $1.90M | $2.94M | $10.80M | $13.86M | $23.10M |
| Total assets | $16.59M | $21.50M | $24.74M | $44.74M | $46.47M | $55.15M | $63.56M | $72.38M | $80.70M | $86.67M |
| Current assets | $5.19M | $9.78M | $13.69M | $14.05M | $15.31M | $23.83M | $32.29M | $40.10M | $48.22M | $53.70M |
| Total liabilities | $3.88M | $5.46M | $4.11M | $4.91M | $5.33M | $7.23M | $9.69M | $8.60M | $8.30M | $8.32M |
| Current liabilities | $2.86M | $4.28M | $3.54M | $3.69M | $3.71M | $5.38M | $7.32M | $5.80M | $5.31M | $5.27M |
| Total equity incl. NCI | $12.71M | $16.04M | $20.63M | $39.83M | $40.70M | $47.48M | $53.88M | $63.78M | $72.40M | $78.35M |
| Temporary (mezzanine) equity | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
| Inventory | $841.67K | $846.12K | $992.40K | $1.09M | $1.08M | $1.08M | $1.07M | $1.27M | $1.46M | $1.55M |
| Accounts receivable | $52.06K | $82.34K | $190.38K | $55.90K | $210.97K | $136.39K | $132.57K | $178.24K | $551.50K | $434.87K |
| Goodwill | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
| Long-term debt | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
| Accounts payable | $1.08M | $2.02M | $1.88M | $1.46M | $1.64M | $2.71M | $3.29M | $2.18M | $1.86M | $2.03M |
Cash flow
| Metric | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$7.15M | -$7.85M | -$6.20M | -$5.90M | -$8.29M | -$8.75M | -$8.23M | -$7.23M | -$5.20M | -$8.49M |
| Capital expenditures | $18.28K | $142.02K | $131.97K | $75.10K | $401.06K | $91.91K | $72.99K | $174.44K | $98.63K | $402.29K |
| Investing cash flow | -$168.28K | -$142.02K | -$329.42K | $2.17M | $17.07M | $7.36M | $266.01K | $4.17M | -$4.04M | $16.67M |
| Financing cash flow | $2.74M | $4.33M | $6.97M | $4.06M | $429.00K | $354.75K | Unavailable | Unavailable | Unavailable | Unavailable |
| Net change in cash | -$4.58M | -$3.65M | $440.66K | $328.76K | $9.21M | -$1.03M | -$7.86M | -$3.06M | -$9.24M | $8.18M |
| Stock-based compensation | $213.75K | $219.11K | $291.98K | $500.58K | $580.26K | $875.23K | $1.32M | $1.05M | $1.50M | $1.57M |
| Common dividends paid | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
| Common share repurchases | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
| Depreciation & amortization | $201.84K | $255.44K | $267.57K | $267.38K | $291.41K | $280.44K | $357.12K | $351.24K | $338.34K | $330.57K |
Derived
| Metric | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Free cash flow | -$7.17M | -$7.99M | -$6.33M | -$5.98M | -$8.69M | -$8.84M | -$8.30M | -$7.40M | -$5.30M | -$8.89M |
| Gross margin | 72.7% | -32.8% | 46.0% | 81.9% | 80.3% | 57.1% | -70.8% | 53.6% | 92.0% | 49.9% |
| Operating margin | -3732.5% | -6309.1% | -10056.7% | -4824.5% | -4946.1% | -17009.7% | -7973.9% | -1596.4% | -289.1% | -2192.9% |
| FCF margin | -4316.7% | -5473.2% | -2398.9% | -4113.1% | -5333.6% | -17576.9% | -5561.0% | -1154.8% | -199.6% | -1900.7% |
| SBC / revenue | 128.7% | 150.1% | 110.6% | 344.3% | 356.2% | 1740.8% | 882.9% | 163.1% | 56.4% | 335.8% |
| Current ratio | 1.81x | 2.28x | 3.87x | 3.81x | 4.12x | 4.43x | 4.41x | 6.92x | 9.09x | 10.19x |
| Revenue YoY growth | 2.0% | 190.3% | 76.7% | -77.3% | -93.9% | -89.3% | -95.8% | -73.9% | 1243.2% | -22.3% |
| Net margin | -3782.4% | Unavailable | -9755.1% | -4049.3% | -4745.0% | Unavailable | -7387.4% | -1512.4% | Unavailable | Unavailable |
| R&D / revenue | 2499.4% | 4065.7% | 1932.0% | 3082.0% | 2877.3% | 9686.4% | 3219.1% | 761.2% | 211.3% | 1214.0% |
| CapEx / revenue | 11.0% | 97.3% | 50.0% | 51.7% | 246.2% | 182.8% | 48.9% | 27.2% | 3.7% | 86.0% |
| Long-term debt / equity | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
| Effective tax rate | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open CODX in the interactive workspace to inspect any figure back to its filing.
Source filings
10-Q · Filed 2026-08-13View SEC filing
10-Q · Filed 2026-05-14View SEC filing
10-K · Filed 2026-03-31View SEC filing
10-Q · Filed 2025-11-13View SEC filing
10-Q · Filed 2025-08-14View SEC filing
10-Q · Filed 2025-05-08View SEC filing
Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.